Moderna advances late-stage development of its vaccine against COVID-19

Moderna, Inc. announced progress on late-stage development of mRNA-1273, the company’s mRNA vaccine candidate against COVID-19. Moderna has finalized the Phase 3 study protocol based on feedback from the U.S. Food and Drug Administration (FDA).